ITI Pharma And Healthcare Fund - Regular Plan - Growth Option
Category: Equity: Sectoral-Pharma and Healthcare
Launch Date: 08-11-2021
AUM:
₹ 276.23 Cr
Expense Ratio
2.63%
Benchmark
Nifty Healthcare TRI
ISIN
INF00XX01BL5
Minimum Investment
5000.0
Minimum Topup
1000.0
Minimum SIP Amount
500
Fund Manager
Mr. Animesh Singh and Mr. Nilay Dalal
| Fund Performance | 1Y (%) | 3Y (%) | 5Y (%) |
|---|---|---|---|
| ITI Pharma And Healthcare Fund - Regular Plan - Growth Option | 9.86 | 17.58 | - |
| NIFTY Healthcare TRI | 13.37 | 20.29 | 13.35 |
If you invested in this fund:
In the past (time duration):
Total value today:
0
Returns:
0%
If you invested in this fund:
In the past (time duration):
Total value today:
0
Returns:
0%
Overview
NAV
18.0725
Last change
-0.06 (-0.3104%)
Fund Size (AUM)
₹ 276.23 Cr
Performance
13.0% (Inception)
Asset Allocation
Equity
Debt
Others
Nav Movement
Investment Objective
The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare. However, there can be no assurance that the investment objective of the scheme would be achieved.
Fund Manager
Mr. Animesh Singh and Mr. Nilay Dalal
Riskometer
Very High
Top 10 Holdings
| Company | Holdings (%) |
|---|---|
| SUN PHARMACEUTICAL INDUSTRIES LTD. EQ NEW F.V. RE.1/- | 13.34 |
| DIVIS LABORATORIES LIMITED EQ NEW RS. 2/- | 6.79 |
| APOLLO HOSPITALS ENTERPRISE LIMITED EQ NEW F.V. RS.5/- | 6.22 |
| Dr. Reddys Laboratories Ltd | 5.44 |
| MAX HEALTHCARE INSTITUTE LIMITED EQ | 5.41 |
| CIPLA LIMITED EQ NEW FV RS.2/- | 4.6 |
| TORRENT PHARMACEUTICALS LIMITED EQ NEW FV RS.5/- | 4.56 |
| LAURUS LABS LIMITED EQ NEW FV RS. 2/- | 4.4 |
| AUROBINDO PHARMA LIMITED EQ NEW F.V. RE.1/- | 4.1 |
| LUPIN LIMITED EQ NEW F.V. RS.2/- | 3.3 |
Sector Allocation
| Sector | Holdings (%) |
|---|---|
| Healthcare | 92.31 |
| Capital Goods | 2.71 |
| Chemicals | 1.25 |
| Financial Services | 0.51 |